Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.04 USD
Change Today -0.285 / -2.76%
Volume 1.1M
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

660 West Germantown Pike

Suite 100

Plymouth Meeting, PA 19462

United States

Phone: 267-440-4200

Fax: 267-440-4242

Inovio Pharmaceuticals, Inc. develops a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. The company’s DNA-based immune therapies, in combination with its proprietary electroporation delivery devices, are generating immune responses, with therapeutic T cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Products and Product Development The company’s primary focus is to independently and in partnership advance the products developed from its integrated platform consisting of its SynCon vaccine and CELLECTRA electroporation technologies. The company is developing various synthetic vaccines for the prevention or treatment of cancer and chronic infectious diseases. Cancer Synthetic Vaccines The company is advancing a growing pipeline of pre-clinical and clinical therapeutic vaccines targeting a range of cancers. Therapeutic HPV Vaccine-VGX-3100: The company’s VGX-3100 is a therapeutic vaccine designed to raise immune responses against the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. In 2011, the company initiated a randomized, placebo-controlled, double-blind phase II study of VGX-3100 delivered using its CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. Therapeutic HPV Vaccine-VGX-3100 +DNA-Based IL-12 Cytokine: In the first half of 2014, the company expects to initiate two phase I/IIa clinical studies. Prostate Cancer Therapeutic Vaccine-INO-5150: In 2013, Roche Inc. (Roche) exclusively licensed this SynCon vaccine in conjunction with the use of the company’s CELLECTRA electroporation technology for this vaccine as part of a broader partnership agreement with the company. The company’s SynCon design is also intended to provide universal protection against known, as well as new unmatched strains of pathogens, such as influenza. The company completed, clinical programs of its proprietary SynCon vaccines and immunotherapies for HPV-caused pre-cancers and cancers (therapeutic), influenza (preventive), prostate cancer (therapeutic), breast/lung/pancreatic cancer (therapeutic), hepatitis C virus (HCV) (therapeutic), hepatitis B virus (HBV) (therapeutic), HIV, and malaria (preventive and therapeutic). Human Telomerase Reverse Transcriptase (hTERT) Therapeutic Vaccine-INO-1400: In 2013, the company announced that its hTERT DNA cancer vaccine administered with its CELLECTRA adaptive electroporation delivery technology generated immune responses, broke the immune system's tolerance to its self-antigens, induced T cells with a tumor-killing function, and increased the rate of survival in pre-clinical studies. Infectious Disease Synthetic Vaccines Hepatitis B Virus-INO-1800: In 2013, Roche exclusively licensed this SynCon vaccine in conjunction with the use of the company’s CELLECTRA electroporation technology for this vaccine as part of a broader partnership agreement with the company. The company is completing pre-clinical work associated with this vaccine and expects that a phase I/IIa study of this vaccine would be initiated in early 2015. HCV Therapeutic Vaccine: In October 2013, the company’s partner VGX International, Inc. launched a phase I study of this HCV vaccine. Under a 2011 development agreement, VGX International, Inc. is funding IND-enabling, phase I, and phase II studies for this vaccine. They are testing VGX-6150 (INO-8000 with DNA-based IL-28 cytokine) in phase I testing in Korea. Avian Influenza Vaccines: The company’s VGX-3400X candidate targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Universal Influenza Vaccin

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $10.04 USD -0.285

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $19.47 USD -0.01
Argos Therapeutics Inc $8.40 USD -0.31
Dynavax Technologies Corp $23.58 USD -0.58
Genocea Biosciences Inc $12.89 USD +0.10
GenVec Inc $2.87 USD -0.03
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.2x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.